JFL Life Sciences share price & results
- Jun 2026
- Sept 2026
Ahmedabad-based manufacturer of generic pharmaceutical formulations — dry powder injections, B-Lactam and general tablets/capsules, and ORS — sold in bulk to marketers and traders, domestically and abroad.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 11.1 | −4.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 18.8 | +2.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.1 | +48.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 15.91 | +3.5 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -5.63 | −0.3 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 55.69 | −14.7 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −18.0% 1Y
1Y: ₹12.5 on 24 Oct 2025 → ₹10.25. High ₹14.7 (23 Dec 2025), low ₹8.55 (30 Mar 2026).
- Previous close
- ₹10.3
- Market cap
- ₹34 Cr
- 52-week range
- ₹8.55 – ₹14.7
- One year
- −21.76%
- Price to earnings (TTM to Jun 2026)
- 5.00×
- Return on equity (TTM to Jun 2026)
- 15.91%
Overview
- Symbol
- NSE:JFLLIFE
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What JFL Life Sciences Ltd does
Based on the company's own presentations, annual report and earnings calls.
JFL Life Sciences manufactures pharmaceutical formulations at an FDA-approved facility near Ahmedabad, Gujarat. It does not sell under its own brand; instead it sells its products in bulk to pharmaceutical marketers and traders, who route them to end customers, using the same unbranded, bulk-supply model for both domestic and export markets. Domestically it has a PAN-India market presence, and internationally it supplies formulations to developed and developing countries, exporting mainly through merchant exporters to African, Middle Eastern and CIS countries.
- Manufacturing facilities
- 1 (FDA-approved formulation plant near Ahmedabad, Gujarat)
- Product types manufactured
- 4 (dry powder injections, B-Lactam tablets/capsules, general tablets/capsules, ORS)
- Export market presence
- 10 developed and developing countries
- Domestic market coverage
- PAN India
- Export regions
- African, Middle Eastern and CIS countries (via merchant exporters)
- Regulatory registrations abroad
- MOH-registered in Kenya, Nigeria, Yemen, Cambodia & Myanmar; product registrations in Ukraine, Uzbekistan, Kazakhstan
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +48% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 21 | 12 | 12 | 30 | 27 | 63 | 11 |
| Expenses | 37 | 20 | 10 | 10 | 27 | 23 | 60 | 9 |
| Operating profit | 2 | 1 | 1 | 2 | 3 | 3 | 4 | 2 |
| Operating margin | 6.1% | 6.3% | 11.8% | 16.6% | 9.7% | 12.5% | 5.6% | 18.8% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 1 |
| Tax rate | 23.2% | 25.3% | 87.0% | 48.3% | 10.9% | 25.1% | 26.2% | 25.5% |
| Net profit | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 1 |
| EPS (₹ per share) | 0.22 | 0.11 | 0.01 | 0.11 | 0.30 | 0.31 | 0.25 | 0.17 |
| Line item | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 82 | 131 |
| Expenses | 74 | 120 |
| Operating profit | 8 | 12 |
| Other income | 0 | 0 |
| Interest | 1 | 2 |
| Depreciation | 1 | 1 |
| Profit before tax | 6 | 9 |
| Net profit | 4 | 6 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 8 | 11 | 11 | 33 | 33 | 33 |
| Reserves | 3 | 21 | 25 | 6 | 9 | 13 |
| Borrowings | 16 | 7 | 6 | 11 | 11 | 22 |
| Other liabilities | 21 | 10 | 15 | 22 | 32 | 39 |
| Total liabilities | 48 | 49 | 57 | 72 | 86 | 106 |
| Fixed assets | 7 | 7 | 12 | 12 | 12 | 15 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 41 | 42 | 44 | 60 | 74 | 92 |
| Total assets | 48 | 49 | 57 | 72 | 86 | 106 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -6 | 2 | -9 | 8 | -4 | -4 |
| Cash from investing | -2 | -1 | 1 | -6 | 0 | -4 |
| Cash from financing | 7 | -1 | 8 | -2 | 4 | 9 |
| Net cash flow | 0 | 0 | 0 | 0 | 0 | 1 |
| Free cash flow | -8 | 1 | -9 | 2 | -4 | -8 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory days | 72 | 212 | 130 | 149 | 128 | 110 |
| Days payable | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash conversion cycle | 146 | 208 | 246 | 254 | 186 | 165 |
| Working capital days | 74 | 117 | 221 | 181 | 124 | 103 |
| Return on capital employed | 10.0% | 23.0% | 15.0% | 11.0% | 16.0% | 18.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 8.0% | 0.0% | 0.0% |
What the price assumes
AttractiveTo justify its price of ₹10, this stock must grow earnings at -13% every year for 7 years. Our analysis caps realistic growth at ~53%. At that growth it is worth ₹295 — upside of 2783%.
- Growth the price implies
- -13.2% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 52.3% a year
- net profit, FY25–FY26 · EPS 53.1%
- The gap
- -0.7 pp
- 2783% downside if it only repeats history
Ownership
Who owns it
Promoters hold 67.47% as of Sept 2026.
- Promoters 67.47%
- Public 32.53%
Who is on the register
Named in the Sep 2026 filing
Every holder of JFL Life Sciences Ltd above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 44.33% | unchanged | |
| 16.58% | unchanged | |
| 3.98% | unchanged | |
| 1.22% | unchanged | |
| 0.89% | unchanged | |
| 0.37% | unchanged | |
| 0.34% | unchanged | |
| 0.27% | unchanged | |
| 0.21% | unchanged | |
| 0.20% | unchanged | |
| 0.18% | unchanged | |
| 0.12% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for JFL Life Sciences Ltd
Free account: one company. Everything above stays public.
Write why you follow JFL Life Sciences Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse JFL Life Sciences Ltd
Guides on how to read this kind of business and the numbers that matter.